Clinical Validation of Imaging Biomarkers in Mycosis Fungoides
Experimental Dermatology · 2026
DOI: 10.1111/exd.70236 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Experimental Dermatology, 2026. Verfasst von Selinde S Wind und 14 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Drug Research, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Mycosis Fungoides, Skin Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centre for Human Drug Research, Recordati Rare Diseases, Micreos Human Health.
Abstract (Originalsprache)
The composite index lesion severity (CAILS) score is used to monitor disease and therapeutic response in mycosis fungoides (MF), but is limited by interobserver variability and low sensitivity. Emerging imaging techniques, such as multispectral imaging (MSI), colourimetry and laser speckle contrast imaging (LSCI), offer objective alternatives for quantifying CAILS parameters. The aim of this study was to evaluate non‐invasive imaging modalities for objective and reliable quantification of disease extent in MF. Sixty‐six participants were enrolled in two prospective studies: a cross‐sectional discovery cohort to assess baseline characteristics of 35 MF patients (IA–IVB) and 10 healthy controls using CAILS and MSI, and a longitudinal confirmation cohort including 21 early‐stage MF patients (IA–IIA) treated with chlormethine gel 0.016% for 16 weeks, in whom lesional and non‐lesional skin were assessed using CAILS, MSI, colourimetry and LSCI at multiple time points. Candidate biomarkers were required to meet five clinical validation criteria: disease discrimination, repeatability, treatment responsiveness, correlation with CAILS and patient acceptability. In the discovery cohort, MSI detected significant differences in erythema, pigmentation, elevation and desquamation between healthy, non‐lesional and lesional skin. In the confirmation cohort, four candidate biomarkers met all validation criteria: MSI CIELAB a*, MSI average haemoglobin, and colourimetry CIELAB a* (DSMIII) for quantifying erythema, and MSI individual typology angle (ITA) for pigmentation. These biomarkers reliably discriminated lesional from non‐lesional skin ( p ≤ 0.001), showed strong test–retest reliability (CV < 10%, ICC > 0.84), detected treatment effects, showed moderate concordance with CAILS, and were associated with low patient burden (mean 3.4/100). These findings show that MSI‐ and colourimetry‐derived biomarkers can objectively monitor disease extent in MF and complement existing clinical assessments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Human Drug Research, Leiden, the Netherlands.
- Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.
- Leiden Academic Centre for Drug Research, Leiden, the Netherlands.
ORCID-Profile: Elise S M Beljaards, Manon A A Jansen, Robert Rissmann
Förderung
- Centre for Human Drug Research
- Recordati Rare Diseases
- Micreos Human Health
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Zitieren
APA
Wind, S. S., Beljaards, E. S. M., Rijneveld, R., Bruijnincx, L., der Kolk, T. N., Jansen, M. A. A., Yavuz, Y., de Kam, M., Burggraaf, J., Klarenbeek, N., Bosch, J., Quint, K. D., Vermeer, M. H., Rissmann, R., & Next‐Generation ImmunoDermatology Consortium (NGID) (2026). Clinical Validation of Imaging Biomarkers in Mycosis Fungoides. Experimental Dermatology. https://doi.org/10.1111/exd.70236
Vancouver
Wind SS, Beljaards ESM, Rijneveld R, Bruijnincx L, der Kolk TN, Jansen MAA, et al. Clinical Validation of Imaging Biomarkers in Mycosis Fungoides. Experimental Dermatology. 2026. doi:10.1111/exd.70236
BibTeX
@article{Wind2026,
author = {Wind, Selinde S and Beljaards, Elise S M and Rijneveld, Rianne and Bruijnincx, Lisa and der Kolk, Tessa Niemeyer-van and Jansen, Manon A A and Yavuz, Yalcin and de Kam, Marieke and Burggraaf, Jacobus and Klarenbeek, Naomi and Bosch, Jacobus and Quint, Koen D and Vermeer, Maarten H and Rissmann, Robert and Next‐Generation ImmunoDermatology Consortium (NGID), Next‐Generation ImmunoDermatology Consortium (NGID)},
title = {Clinical Validation of Imaging Biomarkers in Mycosis Fungoides},
journal = {Experimental Dermatology},
year = {2026},
doi = {10.1111/exd.70236}
}
EUVIMED